Arrayed screening at the MRC-AZ-University of Cambridge Joint Functional Genomics Screening Laboratory (FGSL)
The Milner Therapeutics Institute recently announced a new partnership with AstraZeneca and the Medical Research Council (MRC) to establish a new state-of-the-art functional genomics screening laboratory (FGSL) based at the Milner Therapeutics Institute. More information.
The call is relevant to UK-based academics, small/medium-sized enterprises (SMEs) and pharma who have complex human in vitro models, such as organoids, co-culture models, etc., amenable to arrayed CRISPR screening. Through setting up collaborations with successful applicants, the FGSL will provide academic researchers, SMEs and pharma with access to arrayed functional genomics screening to better understand the biology represented by the model and where applicable, for target identification.
Please join this webinar to learn more about the joint venture between the MRC, AstraZeneca and the Milner Therapeutics Institute, and the application of arrayed CRISPR screening in uncovering novel genes and biology for disease. This webinar will be an opportunity to answer any questions you may have about the on-going call for project proposals for the FGSL.
